Driver for aerosol drug delivery and aerosol drug delivery system containing the same

Abstract

The present invention discloses a driver for aerosol administration and an aerosol administration system containing the same. The driver includes more than two vertically arranged drug delivery tubes, each of which encloses a drug delivery channel; the driver also includes a confluence and a vertically arranged drug mixing tube, the drug mixing tubes enclose a drug mixing channel; the confluence and each drug delivery tube are located on the same side of the entrance of the drug mixing channel; each platform portion is connected to the confluence; the confluence is connected to the drug mixing channel; a spray hole is also provided on the side wall of the drug mixing channel, the diameter of the spray hole is 0.25-0.6 mm, the depth of the spray hole is 0.4-1.0 mm; the center of the spray hole is 3.0-7.0 mm away from the top of the drug mixing tube. The driver and the aerosol administration system can realize the delivery of more than two drugs, and can make the drugs achieve an ideal dispersion effect.

Description

Technical Field

[0001] The invention relates to a driver for aerosol administration and an aerosol administration system containing the driver. Background Art

[0002] Aerosol refers to a drug-containing, emulsion or suspension and a suitable propellant sealed in a pressure-resistant container with a special valve system. When used, the contents are sprayed out in a mist with the help of the pressure of the propellant. It is used for lung inhalation or directly sprayed on the cavity mucosa, skin and space disinfection. The aerosol tank, valve and valve stem together constitute the aerosol delivery system. The general application of quantitative inhalation aerosol is to fill an aerosol tank in a driver, and then realize the drug delivery process by pressing.

[0003] However, in many cases, it is necessary to use aerosols containing more than two APIs. One approach is to prepare a compound aerosol, that is, to put more than two APIs into a can for administration. This method has certain requirements for drug research and stability; another approach is to administer two or more aerosols containing a single API at the same time.

[0004] Currently, the prior art only has a driver applicable to one aerosol can, but no driver applicable to two or more aerosol cans, thereby failing to achieve simultaneous drug delivery of multiple products. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide a new type of aerosol drug delivery driver and an aerosol drug delivery system containing the same in order to overcome the defect that the prior art still lacks a driver suitable for two or more aerosol cans and thus cannot achieve the simultaneous drug delivery of multiple products. The driver for aerosol drug delivery can insert more than two aerosol delivery systems into it, thereby achieving the delivery of more than two drugs and enabling the drugs to achieve an ideal dispersion effect. The aerosol drug delivery system can achieve the delivery of more than two drugs and enable the drugs to achieve an ideal dispersion effect.

[0006] The present invention solves the above technical problems through the following technical solutions:

[0007] The present invention provides a driver for aerosol drug administration, the driver comprising more than two vertically arranged drug delivery tubes, each of the drug delivery tubes enclosing a drug delivery channel, each of the drug delivery channels being divided into an interface portion and a platform portion in sequence along the drug delivery direction, each of the interface portions being used to cooperate with a valve stem of a corresponding aerosol delivery system, and each of the platform portions being used to enable the valve stem of the aerosol delivery system to spray the drug along the drug delivery direction and restrict the valve stem of the aerosol delivery system from moving along the drug delivery direction when the valve stem of the aerosol delivery system is pressed; the driver also comprises A confluence and a vertically arranged drug mixing tube, the drug mixing tubes enclose a drug mixing channel; the confluence and each of the drug delivery tubes are located on the same side of the entrance of the drug mixing channel; each of the platform parts is connected to the confluence; the confluence is connected to the drug mixing channel; a spray hole is also provided on the side wall of the drug mixing channel, the spray hole is used to spray the drug, the diameter of the spray hole is 0.25-0.6 mm, the depth of the spray hole is 0.4-1.0 mm; the center of the spray hole is 3.0-7.0 mm away from the top of the drug mixing tube.

[0008] In the above-mentioned driver, preferably, the number of the drug delivery tubes is 2.

[0009] In the above-mentioned driver, preferably, each of the drug delivery tubes is arranged in the same manner, and each of the platform portions is located at the same height in the drug delivery tube.

[0010] In the above driver, preferably, the interface portion is a vertically arranged cylindrical channel. More preferably, the distance between the axes of two adjacent interface portions is 18-22 mm, and further preferably, the distance between the axes of two adjacent interface portions is 18-20 mm.

[0011] In the above driver, preferably, the inner diameter of the interface portion is equal to the outer diameter of the valve stem of the aerosol delivery system, and generally there is a processing tolerance of 1%-5%.

[0012] In the above-mentioned driver, preferably, the platform portion is a vertically arranged cylindrical channel.

[0013] In the above-mentioned driver, preferably, the inner diameter of the platform portion is ±0.6 mm of the inner diameter of the valve stem of the aerosol delivery system.

[0014] In the above driver, preferably, the platform portion is connected to the confluence portion via a transition portion, and the transition portion is a circular arc pipe segment that enables a smooth transition between the platform portion and the confluence portion. More preferably, the inner diameter of the transition portion is equal to the inner diameter of the interface portion.

[0015] In the above-mentioned driver, preferably, the inner diameter of the drug mixing tube is 2.5-3.3 mm, more preferably 2.8-3.2 mm.

[0016] In the above-mentioned driver, preferably, the outer diameter of the drug mixing tube is 3.5 mm.

[0017] In the above-mentioned driver, preferably, the drug mixing channel is a vertically arranged cylindrical channel.

[0018] In the above-mentioned driver, the depth of the spray hole refers to the depth of the spray hole in the direction perpendicular to the drug mixing tube. The diameter of the spray hole is preferably 0.25-0.55 mm. The depth of the spray hole is preferably 0.45-1.0 mm. The distance between the center of the spray hole and the top of the drug mixing tube is preferably 3.5-6.0 mm.

[0019] The number of the spray hole is preferably one.

[0020] In the above-mentioned driver, preferably, the driver is made of plastic, more preferably PET material, PBT material, PE material or PP material. The driver can be made by one-time molding through mold processing, for example.

[0021] In the above driver, the height of the driver is preferably 40-80 mm.

[0022] In the above-mentioned driver, the driver further has a shell, and the shell can fix the drug delivery tube and does not affect the spray hole to spray the drug.

[0023] The present invention also provides an aerosol dosing system, which includes the aforementioned aerosol dosing driver and two or more aerosol delivery systems, wherein the valve stem of each aerosol delivery system cooperates with one of the interface parts; the inner hole diameter of the valve stem of the aerosol delivery system is 2.5-3.3 mm.

[0024] In the above-mentioned aerosol drug delivery system, the aerosol delivery system generally includes a valve stem, a valve and a tank body containing an aerosol; after being filled with the drug, the valve of the aerosol delivery system and the tank body of the aerosol delivery system are sealed by a sealing device, and the sealing is achieved by a rubber gasket.

[0025] In the above-mentioned aerosol drug delivery system, preferably, the inner diameter of the valve stem of the aerosol delivery system is 2.8-3.2 mm, for example, 3.16 mm.

[0026] In the above-mentioned aerosol drug delivery system, preferably, the outer diameter of the valve stem of the aerosol delivery system is 3.5 mm.

[0027] In the above aerosol drug delivery system, preferably, the distance between the axes of the valve stems of two adjacent aerosol delivery systems is 18-22 mm.

[0028] In the above-mentioned aerosol drug delivery system, preferably, the outer diameter of the valve of the aerosol delivery system is 14-16 mm.

[0029] In the above-mentioned aerosol drug delivery system, preferably, the valve of the aerosol delivery system contains a spring assembly, and the spring assembly is used to restore the tank of the aerosol delivery system to a balanced position after being pressed, and the expansion and contraction amount of the spring assembly is 0.6-1.2 mm.

[0030] In the above-mentioned aerosol drug delivery system, preferably, the outer diameter of the tank of the aerosol delivery system is 14-16 mm.

[0031] In the above-mentioned aerosol drug delivery system, preferably, the bottom of each tank of the aerosol delivery system is at the same height.

[0032] In the above-mentioned aerosol drug delivery system, preferably, the aerosol drug delivery system is further provided with a cap, and the cap is provided with a groove that matches the bottom of the tank body of the aerosol delivery system, and the cap can simultaneously move the tank body of the aerosol delivery system downward in a vertical direction. In the above-mentioned technical solution, the design of the groove can fix the tank body, and during the pressing process, it can ensure that the two tank bodies are pressed at the same time.

[0033] In the above-mentioned aerosol dosing system, preferably, the aerosol in the tank body of at least one of the aerosol delivery systems is a β-receptor agonist and the aerosol in the tank body of at least one of the aerosol delivery systems is an inhaled glucocorticoid, or, the aerosol in the tank body of at least one of the aerosol delivery systems is a β-receptor agonist and the aerosol in the tank body of at least one of the aerosol delivery systems is an anticholinergic inhibitor; more preferably, the aerosol in the tank body of at least one of the aerosol delivery systems is a β-receptor agonist, the aerosol in the tank body of at least one of the aerosol delivery systems is an inhaled glucocorticoid and the aerosol in the tank body of at least one of the aerosol delivery systems is an anticholinergic inhibitor.

[0034] Among them, the beta receptor agonist can be a long-acting beta receptor agonist or a short-acting beta receptor agonist, the long-acting beta receptor agonist refers to a beta receptor agonist whose action duration is 11-12 hours, and the short-acting beta receptor agonist refers to a beta receptor agonist whose action duration is 4-6 hours, preferably salmeterol aerosol, formoterol aerosol, vilanterol aerosol, salbutamol aerosol or levosalbutamol aerosol, more preferably short-acting salbutamol sulfate aerosol or long-acting salmeterol aerosol.

[0035] Wherein, the inhaled glucocorticoid is preferably fluticasone aerosol or budesonide aerosol, more preferably fluticasone propionate aerosol.

[0036] Wherein, the anticholinergic inhibitor is preferably ipratropium bromide aerosol, tiotropium bromide aerosol or glycopyrrolate aerosol.

[0037] In a preferred embodiment of the above-mentioned aerosol delivery system, the combination of the beta receptor agonist and the inhaled glucocorticoid is as follows: a combination of long-acting salmeterol aerosol and fluticasone aerosol, or a combination of long-acting formoterol aerosol and budesonide aerosol, or a combination of long-acting vilanterol aerosol and fluticasone aerosol.

[0038] In a preferred embodiment of the above-mentioned aerosol delivery system, the combination of the beta receptor agonist and the inhaled glucocorticoid is as follows: a combination of short-acting salbutamol sulfate aerosol and budesonide aerosol, or a combination of long-acting salmeterol aerosol and fluticasone propionate aerosol.

[0039] In a preferred embodiment of the above-mentioned aerosol delivery system, the combination of the beta receptor agonist and the anticholinergic inhibitor is as follows: a combination of a short-acting salbutamol aerosol and an ipratropium bromide aerosol, or a combination of a short-acting levosalbutamol aerosol and a tiotropium bromide aerosol, or a combination of a long-acting formoterol aerosol and a glycopyrrolate aerosol, or a combination of a long-acting vilanterol aerosol and a umeclidinium bromide aerosol.

[0040] In a preferred embodiment of the above-mentioned aerosol drug delivery system, the combination of the beta receptor agonist, the inhaled glucocorticoid and the anticholinergic inhibitor is as follows: a combination of long-acting vilanterol aerosol, umeclidinium bromide aerosol and budesonide aerosol.

[0041] In the above preferred embodiment, the definitions of the long-acting salmeterol aerosol, the long-acting formoterol aerosol and the long-acting vilanterol aerosol are the same as the definition of the long-acting beta receptor agonist; the definitions of the short-acting salbutamol aerosol, the short-acting levosalbutamol aerosol and the short-acting salbutamol sulfate aerosol are the same as the definition of the short-acting beta receptor agonist.

[0042] The positive and progressive effect of the present invention is that the driver for aerosol drug administration can insert more than two aerosol delivery systems therein, thereby achieving the delivery of more than two drugs and enabling the drugs to achieve an ideal dispersion effect. The aerosol drug administration system can achieve the delivery of more than two drugs and enable the drugs to achieve an ideal dispersion effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1A cross-sectional view of a vertical plane where the axis of the drug delivery channel and the axis of the drug mixing channel of the driver of Examples 1-5 of the present invention are located;

[0044] Figure 2 A cross-sectional view of a vertical plane where the axis of the spray hole of the driver of Embodiments 1-5 of the present invention is located;

[0045] Figure 3 It is a cross-sectional view of the drug delivery system of embodiments 1-5 of the present invention along the vertical plane where the axis of the drug delivery channel of the driver and the axis of the drug mixing channel are located.

[0046] Description of reference numerals:

[0047] Drug delivery tube 10

[0048] Interface unit 11

[0049] Platform 12

[0050] Transition 20

[0051] Drug mixing tube 30

[0052] Drug mixing channel 31

[0053] Spray hole 32

[0054] Depth of spray hole h

[0055] Aerosol Delivery Systems40

[0056] Junction 50 DETAILED DESCRIPTION

[0057] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0058] In the following examples, salbutamol sulfate aerosol (200 presses per bottle, each press containing 100 μg of salbutamol sulfate) and budesonide aerosol (100 presses per bottle, each press containing 200 μg of budesonide) are commercially available products of Shanghai Pharma Xinyi Pharmaceutical Co., Ltd., and fluticasone propionate aerosol and salmeterol aerosol are commercially available products of GlaxoSmithKline Pharmaceuticals Co., Ltd.

[0059] In the following examples, the long-acting beta receptor agonist refers to a beta receptor agonist whose action lasts for 11-12 hours, and the short-acting beta receptor agonist refers to a beta receptor agonist whose action lasts for 4-6 hours.

[0060] Examples 1-5

[0061] (1) Actuator for aerosol administration

[0062] like Figure 1 and Figure 2 The driver for aerosol administration shown in the figure comprises more than two vertically arranged drug delivery tubes 10, each drug delivery tube 10 is enclosed to form a drug delivery channel, each drug delivery channel is divided into an interface portion 11 and a platform portion 12 in sequence along the drug delivery direction, each interface portion 11 is used to cooperate with the valve stem of the corresponding aerosol delivery system, and each platform portion 12 is used to make the valve stem of the aerosol delivery system spray the drug along the drug delivery direction and restrict the valve stem of the aerosol delivery system from moving along the drug delivery direction when the valve stem of the aerosol delivery system is pressed; the driver also comprises a confluence portion 50 and a vertically arranged drug mixing tube 30, the drug mixing tube 30 is enclosed to form a drug mixing channel 31; the confluence portion 50 and each drug delivery tube 10 are located on the same side of the entrance of the drug mixing channel 31; each platform portion 12 is connected to the confluence portion 50; the confluence portion 50 is connected to the drug mixing channel 31; a spray hole 32 is also provided on the side wall of the drug mixing channel 31, and the spray hole 32 is used to spray the drug.

[0063] There are two drug delivery tubes 10 .

[0064] The configuration of each drug delivery tube 10 is the same, and each platform portion 12 is located at the same height in the drug delivery tube 10 .

[0065] The interface portion 11 is a vertically arranged cylindrical channel.

[0066] The inner diameter of the interface portion 11 is equal to the outer diameter of the valve stem of the aerosol delivery system, and generally there is a processing tolerance of 1%-5%.

[0067] The platform portion 12 is a vertically arranged cylindrical channel.

[0068] The inner diameter of the platform portion 12 is ±0.6 mm of the inner diameter of the valve stem of the aerosol delivery system.

[0069] The platform portion and the confluence portion 50 are connected via a transition portion. The transition portion 20 is an arc pipe section that enables a smooth transition between the platform portion 12 and the confluence portion 50 . The inner diameter of the transition portion 20 is equal to the inner diameter of the interface portion 11 .

[0070] Wherein, the outer diameter of the drug mixing tube 30 is 3.5 mm.

[0071] The drug mixing channel 31 is a vertically arranged cylindrical channel.

[0072] The depth h of the spray hole refers to the depth of the spray hole 32 in the direction perpendicular to the drug mixing tube 30 (e.g. Figure 2 The number of the spray hole 32 is one.

[0073] The driver is made of plastic, such as PET, PBT, PE or PP.

[0074] The driver further comprises a housing, which can fix the drug delivery tube 10 and does not affect the spray hole 32 from spraying the drug.

[0075] (2) Aerosol drug delivery system

[0076] like Figure 3 The aerosol drug delivery system shown in the figure comprises the aerosol drug delivery device as described above. Figure 1 and Figure 2 The driver shown has more than two aerosol delivery systems 40 , and the valve stem of each aerosol delivery system 40 cooperates with an interface portion 11 .

[0077] The aerosol delivery system 40 generally includes a valve stem, a valve and a tank body containing an aerosol; after being filled with medicine, the valve of the aerosol delivery system 40 and the tank body of the aerosol delivery system 40 are sealed by a sealing device and sealed by a rubber gasket.

[0078] The outer diameter of the valve stem of the aerosol delivery system 40 is 3.5 mm.

[0079] The outer diameter of the valve of the aerosol delivery system 40 is 14-16 mm.

[0080] The valve of the aerosol delivery system 40 contains a spring assembly, which is used to restore the tank of the aerosol delivery system 40 to a balanced position after being pressed, and the expansion and contraction amount of the spring assembly is 0.6-1.2 mm.

[0081] The outer diameter of the tank of the aerosol delivery system 40 is 14-16 mm.

[0082] The bottom of the tank of each aerosol delivery system 40 is at the same height.

[0083] The aerosol drug delivery system is also provided with a cap, which is provided with a groove that matches the bottom of the tank body of the aerosol delivery system 40, and the cap can simultaneously move the tank body of the aerosol delivery system 40 downward in the vertical direction. In the above technical solution, the design of the groove can fix the tank body, and during the pressing process, it can ensure that the two tank bodies are pressed at the same time.

[0084] Among them, the relevant structural parameters of the driver for aerosol drug delivery and the aerosol drug delivery system are shown in the table below.

[0085] The types and combinations of aerosols in the aerosol delivery system 40 in Examples 1-5 correspond to the contents of the relevant tables in Effect Examples 1-5, respectively.

[0086]

[0087] Effect Example 1-2 Combination of short-acting salbutamol sulfate aerosol and budesonide aerosol

[0088] Among them, the specifications of salbutamol sulfate aerosol are: 100 micrograms / press; budesonide aerosol: 200 micrograms / press, 100 micrograms / press. The HPLC content determination results of the drug delivery system containing the following combination of aerosol delivery system 40 are as follows:

[0089]

[0090] Effect Example 3-5 Combination of Fluticasone Propionate Aerosol and Long-acting Salmeterol Aerosol

[0091] Among them, the specifications of fluticasone propionate aerosol are: 50 micrograms / press, 125 micrograms / press, and 250 micrograms / press; salmeterol aerosol: 25 micrograms / press. The HPLC content determination results of the drug delivery system containing the following combination of aerosol delivery system 40 are as follows:

[0092]

[0093] Although the specific embodiments of the present invention are described above, it should be understood by those skilled in the art that this is only for illustration and the protection scope of the present invention is defined by the appended claims. Those skilled in the art may make various changes or modifications to these embodiments without departing from the principles and essence of the present invention, but these changes and modifications all fall within the protection scope of the present invention.

Claims

1. A driver for aerosol administration, characterized in that: The driver includes more than two vertically arranged drug delivery tubes, each of which encloses a drug delivery channel, and each of which is divided into an interface portion and a platform portion in sequence along the drug delivery direction, each of which is used to cooperate with a valve stem of a corresponding aerosol delivery system, and each of which is used to make the valve stem of the aerosol delivery system spray the drug along the drug delivery direction and restrict the valve stem of the aerosol delivery system from moving along the drug delivery direction when the valve stem of the aerosol delivery system is pressed; the driver also includes a confluence portion and a vertically arranged The drug mixing tube is disposed in the medicine mixing tube, and the drug mixing tube encloses a drug mixing channel; the confluence portion and each of the drug delivery tubes are located on the same side of the entrance of the drug mixing channel; each of the platform portions is communicated with the confluence portion; the confluence portion is communicated with the drug mixing channel; a spray hole is further provided on the side wall of the drug mixing channel, the spray hole is used to spray the drug, the diameter of the spray hole is 0.25-0.6 mm, the depth of the spray hole is 0.4-1.0 mm; the distance between the center of the spray hole and the top of the drug mixing tube is 3.0-7.0 mm; The platform portion is connected to the confluence portion via a transition portion, and the transition portion is a circular arc pipe segment that enables a smooth transition between the platform portion and the confluence portion; the inner diameter of the transition portion is equal to the inner diameter of the interface portion; The interface portion is a vertically arranged cylindrical channel, and the distance between the axes of two adjacent interface portions is 18-22 mm; The inner diameter of the drug mixing tube is 2.5-3.3 mm; The height of the driver is 40-80 mm; The valve stem of the aerosol delivery system has an inner hole diameter of 2.5-3.3 mm.

2. The aerosol administration driver according to claim 1, characterized in that: The number of the drug delivery tubes is 2; And / or, each of the drug delivery tubes is arranged in the same manner, and each of the platform portions is located at the same height in the drug delivery tube.

3. The aerosol administration driver according to claim 1, characterized in that: The distance between the axes of two adjacent interface parts is 18-20 mm; and / or, the inner diameter of the interface portion is equal to the outer diameter of the valve stem of the aerosol delivery system; And / or, the platform portion is a vertically arranged cylindrical channel; And / or, the inner diameter of the platform portion is ±0.6 mm of the inner diameter of the valve stem of the aerosol delivery system.

4. The aerosol administration driver according to claim 1, characterized in that: The inner diameter of the drug mixing tube is 2.8-3.2 mm; And / or, the outer diameter of the drug mixing tube is 3.5 mm; And / or, the drug mixing channel is a vertically arranged cylindrical channel.

5. The aerosol administration driver according to claim 1, characterized in that: The diameter of the spray hole is 0.25-0.55 mm; and / or, the depth of the spray hole is 0.45-1.0 mm; and / or, the distance between the center of the spray hole and the top of the drug mixing tube is 3.5-6.0 mm; And / or, the number of the spray hole is 1.

6. The actuator for aerosol administration according to claim 1, characterized in that: The driver is made of plastic; And / or, the driver further comprises a housing, and the housing can fix the drug delivery tube without affecting the spray hole to spray the drug.

7. The actuator for aerosol administration according to claim 6, characterized in that: The driver is made of PET material, PBT material, PE material or PP material.

8. An aerosol drug delivery system, characterized in that: The aerosol drug delivery system comprises the driver for aerosol drug delivery as claimed in any one of claims 1 to 7 and two or more aerosol delivery systems, wherein the valve stem of each aerosol delivery system cooperates with one of the interface parts.

9. The aerosol delivery system according to claim 8, characterized in that: The valve stem of the aerosol delivery system has an inner bore diameter of 2.8-3.2 mm; and / or, the valve stem of the aerosol delivery system has an outer diameter of 3.5 mm; and / or, the distance between the axes of the valve stems of two adjacent aerosol delivery systems is 18-22 mm; and / or, the outer diameter of the valve of the aerosol delivery system is 14-16 mm; And / or, the valve of the aerosol delivery system contains a spring assembly, the spring assembly is used to restore the tank of the aerosol delivery system to a balanced position after being pressed, and the expansion and contraction amount of the spring assembly is 0.6-1.2 mm; and / or, the outer diameter of the tank of the aerosol delivery system is 14-16 mm; and / or, the bottom of each tank of the aerosol delivery system is at the same height; And / or, the aerosol drug delivery system is further provided with a cap, the cap is provided with a groove matching with the bottom of the tank body of the aerosol delivery system, and the cap can simultaneously move the tank body of the aerosol delivery system downward in a vertical direction.

10. The aerosol delivery system according to claim 8 or 9, characterized in that: In the aerosol dosing system, the aerosol in the tank of at least one aerosol delivery system is a beta receptor agonist and the aerosol in the tank of at least one aerosol delivery system is an inhaled glucocorticoid, or the aerosol in the tank of at least one aerosol delivery system is a beta receptor agonist and the aerosol in the tank of at least one aerosol delivery system is an anticholinergic inhibitor.

11. The aerosol delivery system according to claim 10, wherein: In the aerosol dosing system, the aerosol in the tank of at least one aerosol delivery system is a beta receptor agonist, the aerosol in the tank of at least one aerosol delivery system is an inhaled glucocorticoid, and the aerosol in the tank of at least one aerosol delivery system is an anticholinergic inhibitor.

12. The aerosol delivery system according to claim 10, wherein: The beta receptor agonist is a long-acting beta receptor agonist or a short-acting beta receptor agonist. The long-acting beta receptor agonist refers to a beta receptor agonist whose action duration is 11-12 hours, and the short-acting beta receptor agonist refers to a beta receptor agonist whose action duration is 4-6 hours.

13. The aerosol delivery system according to claim 12, wherein: The beta receptor agonist is salmeterol aerosol, formoterol aerosol, vilanterol aerosol, salbutamol aerosol or levosalbutamol aerosol.

14. The aerosol delivery system according to claim 12, wherein: The beta receptor agonist is a short-acting salbutamol sulfate aerosol or a long-acting salmeterol aerosol.

15. The aerosol delivery system according to claim 10, wherein: The inhaled glucocorticoid is fluticasone aerosol or budesonide aerosol.

16. The aerosol delivery system according to claim 15, wherein: The inhaled glucocorticoid is fluticasone propionate aerosol.

17. The aerosol delivery system according to claim 10, wherein: The anticholinergic inhibitor is ipratropium bromide aerosol, tiotropium bromide aerosol or glycopyrrolate aerosol.

18. The aerosol delivery system according to claim 10, wherein: The combination of the beta receptor agonist and the inhaled glucocorticoid is as follows: a combination of long-acting salmeterol aerosol and fluticasone aerosol, or a combination of long-acting formoterol aerosol and budesonide aerosol, or a combination of long-acting vilanterol aerosol and fluticasone aerosol; or, the combination of the beta receptor agonist and the inhaled glucocorticoid is as follows: a combination of short-acting salbutamol sulfate aerosol and budesonide aerosol, or a combination of long-acting salmeterol aerosol and fluticasone propionate aerosol; Alternatively, the beta receptor agonist and the anticholinergic inhibitor are combined in the following manner: a combination of a short-acting salbutamol aerosol and an ipratropium bromide aerosol, or a combination of a short-acting levosalbutamol aerosol and a tiotropium bromide aerosol, or a combination of a long-acting formoterol aerosol and a glycopyrrolate aerosol, or a combination of a long-acting vilanterol aerosol and an umeclidinium bromide aerosol; Alternatively, the combination of the beta receptor agonist, the inhaled glucocorticoid and the anticholinergic inhibitor is as follows: a combination of long-acting vilanterol aerosol, umeclidinium bromide aerosol and budesonide aerosol.

Images